Lantern Pharma Inc (LTRN) Q4 2025 Earnings Call Highlights: Strategic Advances Amid Financial ... [Yahoo! Finance]
Lantern Pharma Inc. (LTRN)
Company Research
Source: Yahoo! Finance
Positive Points Lantern Pharma Inc ( NASDAQ:LTRN ) achieved clinical validation across multiple programs in 2025, establishing a foundation for future growth. The company reported a 19% reduction in total operating expenses year over year, reflecting disciplined execution. Lantern Pharma Inc ( NASDAQ:LTRN ) received FDA IND clearance for its pediatric CNS cancer program, marking a significant regulatory milestone. The company's AI-driven clinical pipeline encompasses multiple drug candidates with a combined estimated annual market potential exceeding $15 billion. Lantern Pharma Inc ( NASDAQ:LTRN ) has successfully dosed over 100 patients across its programs, demonstrating clear linkage to mechanisms and patient value. Negative Points Lantern Pharma Inc ( NASDAQ:LTRN ) reported a net loss of approximately $17.1 million for the full year 2025. The company anticipates needing to raise substantial additional funding in the near future to continue operations. There was a
Show less
Read more
Impact Snapshot
Event Time:
LTRN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LTRN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LTRN alerts
High impacting Lantern Pharma Inc. news events
Weekly update
A roundup of the hottest topics
LTRN
News
- Emerging Data for Lantern Pharma's Investigational Drug LP-300 Demonstrates 8.3-Month Median Progression-Free Survival in Patients with EGFR L858R Lung Cancer After Targeted Therapy Failure — With No Added Toxicity [Yahoo! Finance]Yahoo! Finance
- Emerging Data for Lantern Pharma’s Investigational Drug LP-300 Demonstrates 8.3-Month Median Progression-Free Survival in Patients with EGFR L858R Lung Cancer After Targeted Therapy Failure — With No Added ToxicityBusiness Wire
- Lantern Pharma Launches withZeta.ai — the World's First Multi-Agentic A.I. Co-Scientist for Rare Cancer Drug Discovery & Development — Subscriptions Now Open; Debut Events at Nasdaq MarketSite on 4/16 and at AACR 2026 from 4/17 to 4/22 [Yahoo! Finance]Yahoo! Finance
- Lantern Pharma Launches withZeta.ai — the World’s First Multi-Agentic A.I. Co-Scientist for Rare Cancer Drug Discovery & Development — Subscriptions Now Open; Debut Events at Nasdaq MarketSite on 4/16 and at AACR 2026 from 4/17 to 4/22Business Wire
- Lantern Pharma Inc. (LTRN) Shareholder/Analyst Call Transcript [Seeking Alpha]Seeking Alpha
LTRN
Earnings
- 8/13/25 - Beat
LTRN
Sec Filings
- 4/16/26 - Form SCHEDULE
- 4/10/26 - Form 8-K
- 4/3/26 - Form SCHEDULE
- LTRN's page on the SEC website